Goldman Sachs Initiates LifePoint Health With Conviction Buy

Analysts at Goldman Sachs initiated coverage on

with a Conviction Buy rating. The target price for LifePoint Health is set to $92. LifePoint Health shares have gained 13.78 percent over the past 52 weeks, while the S&P 500 index has surged 7.51 percent in the same period. LifePoint Health shares fell 1.05 percent to close at $73.39 yesterday.